The Latest Breaking News from Tonix Pharmaceuticals

Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) have rallied 30% over the past five sessions, though are marginally lower Thursday afternoon, as investors anticipate a key catalyst for the company.

Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) are trading sharply higher Tuesday morning following the release of the company’s second-quarter financial results and operational update.

Tonix Pharmaceuticals' innovative approach to fibromyalgia treatment positions the company for substantial market disruption and long-term growth.

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower by 6.03% to $2.96 during Thursday’s pre-market session. The company announced Thursday that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a Chatham, New Jersey-based clinical-stage biopharmaceutical company, announced on Wednesday the issuance of a patent that forms the basis for the company's developmental vaccine against monkeypox and smallpox. 

  Tonix Pharmaceuticals (NASDAQ:TNXP) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Upgrades